Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylene blue + ropivacaine vs ropivacaine alone for TAP block in laparoscopic radical colorectal cancer surgery
ChiCTR2600125533Phase 4Not yet recruiting
- Sponsor
- Shanxi Provincial People's Hospital
- Start
- May 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methylene blue and ropivacaine in colorectal cancer (CRC) (2 arms), sponsored by Shanxi Provincial People's Hospital. Primary endpoint: Visual Analogue Scale (VAS) score (static and dynamic). Planned start May 2026; status: not yet recruiting.
02
Drugs
methylene blueropivacaine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600125533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125533.